Data gathered: February 9
Alternative Data for Exelixis
Alternative Data | Value | 3m Change | Trend | Benchmark | |
---|---|---|---|---|---|
Job Posts | 66 | Sign up | Sign up | Sign up | |
Sentiment | 96 | Sign up | Sign up | Sign up | |
Employee Rating | 42 | Sign up | Sign up | Sign up | |
Google Trends | 13 | Sign up | Sign up | Sign up | |
4chan Mentions | N/A | Sign up | Sign up | Sign up | |
Reddit Mentions | N/A | Sign up | Sign up | Sign up | |
Stocktwits Mentions | 4 | Sign up | Sign up | Sign up | |
Stocktwits Subscribers | 12,000 | Sign up | Sign up | Sign up | |
Twitter Followers | 5,682 | Sign up | Sign up | Sign up | |
News Mentions | N/A | Sign up | Sign up | Sign up | |
Customer reviews | N/A | Sign up | Sign up | Sign up | |
Business Outlook | 10 | Sign up | Sign up | Sign up | |
Linkedin Employees | 1,456 | Sign up | Sign up | Sign up |
About Exelixis
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

Price | $33.48 |
Target Price | Sign up |
Volume | 1,460,000 |
Market Cap | $9.62B |
Year Range | $21.56 - $37.27 |
Dividend Yield | 0% |
PE Ratio | 21.74 |
Analyst Rating | 60% buy |
Earnings Date | February 11 '25 |
Industry | Biotechnology |
In the news
![]() |
Spire Wealth Management Has $300,000 Holdings in Exelixis, Inc. (NASDAQ:EXEL)February 7 - ETF Daily News |
Zacks.com featured highlights include Pilgrim's Pride, Exelixis, Synchrony and United AirlinesFebruary 6 - Yahoo |
|
EXEL or TECH: Which Is the Better Value Stock Right Now?February 6 - Yahoo |
|
Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key MetricsFebruary 5 - Yahoo |
|
![]() |
Chicago Partners Investment Group LLC Takes Position in Exelixis, Inc. (NASDAQ:EXEL)February 5 - ETF Daily News |
![]() |
Exelixis, Inc. (NASDAQ:EXEL) Receives $36.06 Consensus PT from AnalystsFebruary 4 - ETF Daily News |
Insider Transactions View All
Hessekiel Jeffrey filed to sell 486,059 shares at $36.7. December 2 '24 |
Haley Patrick J. filed to sell 278,665 shares at $35.3. November 26 '24 |
Haley Patrick J. filed to sell 288,665 shares at $34.4. November 19 '24 |
Haley Patrick J. filed to sell 308,046 shares at $34.3. November 19 '24 |
Aftab Dana filed to sell 498,945 shares at $35. November 7 '24 |
Similar companies
Read more about Exelixis (EXEL) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Exelixis?
The Market Cap of Exelixis is $9.62B.
What is Exelixis' PE Ratio?
As of today, Exelixis' PE (Price to Earnings) ratio is 21.74.
When does Exelixis report earnings?
Exelixis will report its next earnings on February 11 '25.
What is the current stock price of Exelixis?
Currently, the price of one share of Exelixis stock is $33.48.
How can I analyze the EXEL stock price chart for investment decisions?
The EXEL stock price chart above provides a comprehensive visual representation of Exelixis' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Exelixis shares. Our platform offers an up-to-date EXEL stock price chart, along with technical data analysis and alternative data insights.
Does EXEL offer dividends to its shareholders?
As of our latest update, Exelixis (EXEL) does not offer dividends to its shareholders. Investors interested in Exelixis should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Exelixis?
Some of the similar stocks of Exelixis are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.